Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

Inclusion Criteria: * Any patient age ≥18 years with melanoma of cutaneous or mucosal origin, and with clinicopathologic stage IIB, IIC, III or IV that has been completely resected * Patients must be able to provide informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of at least 6 months. * Adequate hematologic function. * Adequate renal function * Adequate hepatic function * Patients of both genders must agree to practice effective birth control during the study period and for at least 4 weeks after the last treatment. Exclusion Criteria: * Patients whose primary site of melanoma is ocular. * Are undergoing or have undergone in the past 4 weeks any systemic treatment for melanoma. * Are undergoing or have undergone in the past 2 weeks any surgery or focal radiation therapy. * Have active systemic infections, coagulation disorders (including therapeutic anticoagulation), or other major medical or psychiatric illnesses. * Are known to be positive for hepatitis B surface antigen, anti-Hepatitis C Virus or anti-Human Immunodeficiency Virus (HIV) antibody (because of possible immune effects of these conditions). * Documented history of autoimmune disease, for example, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis. * Any form of primary or secondary immunodeficiency. This would include hereditary disorders such as ataxia-telangiectasia or Wiskott-Aldrich syndrome, or a…